SCYNEXIS, Inc.
(NASDAQ : SCYX)

( )
SCYX After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Other
symbolcompany%chnglast%shortavg$volume
AMRNAmarin Corporation Plc Sponsored ADR
1.68%17.522.0%$170.25m
SAGESAGE Therapeutics, Inc.
-1.79%137.299.5%$121.17m
PRGOPerrigo Co. Plc
-2.26%44.936.8%$100.11m
JAZZJazz Pharmaceuticals Plc
-0.32%128.662.2%$87.44m
GWPHGW Pharmaceuticals PLC Sponsored ADR
1.44%139.266.3%$78.73m
PTLAPortola Pharmaceuticals, Inc.
-3.77%25.537.7%$54.93m
ICPTIntercept Pharmaceuticals, Inc.
-2.22%110.9318.6%$52.57m
AXSMAxsome Therapeutics, Inc.
4.41%8.522.7%$46.12m
MNKMallinckrodt Plc
-3.15%19.9821.1%$40.05m
CTLTCatalent Inc
-0.62%35.392.4%$39.43m
ICLRICON Plc
-0.68%132.284.1%$38.89m
UTHRUnited Therapeutics Corporation
-1.60%113.9014.4%$34.98m
ENDPEndo International Plc
-4.23%9.298.9%$32.66m
HZNPHorizon Pharma plc
0.37%21.927.4%$26.48m
PCRXPacira Pharmaceuticals, Inc.
1.05%40.4610.6%$25.36m

Company Profile

SCYNEXIS, Inc. engages in the development and commercialization of novel anti-infectives, which addresses the significant unmet therapeutic needs. It develops a novel oral and intravenous drug for several fungal infections, including serious and life-threatening invasive fungal infections. The company was founded by Scot Kevin Huber, Terry Eugene Marquardt, Pierre Bernard Jacques Monnet, Russell J. Outcalt, and Yves Joseph Ribeill on November 4, 1999 and is headquartered in Jersey City, NJ.